Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
CROs Step Up Activities in Developing Countries
Outsourcing Veterans Reveal Advantages and Drawbacks of Offshore Trials
- Biopharma companies are increasingly turning to developing nations as sites for clinical trials, driven by a ready supply of patients, the ability to tackle diseases that are rare in industrialized nations, and large potential markets. “Competition for available patients in industrialized nations is a major challenge in new ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.